Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study

Leuk Lymphoma. 2020 Jan;61(1):176-180. doi: 10.1080/10428194.2019.1654100. Epub 2019 Aug 22.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brentuximab Vedotin
  • Hodgkin Disease* / drug therapy
  • Humans
  • Immunoconjugates*
  • Lymphoma, Large-Cell, Anaplastic* / drug therapy
  • Neoplasm Recurrence, Local / drug therapy
  • Retreatment
  • Retrospective Studies

Substances

  • Immunoconjugates
  • Brentuximab Vedotin